U.S. FDA approves Impel NeuroPharma's acute migraine treatment
03/09/2021 13:53
Sept 3 (Reuters) - The U.S. Food and Drug Administration has approved Impel NeuroPharma Inc's IMPL.O intranasal spray to treat acute migraine, the drug developer said on Friday. (Reporting by Mrinalika Roy in Bengaluru; Editing by Ramakrishnan M.)
Recent news on IPI Legacy Liquidation Co
See all newsBrief: Impel Pharmaceuticals- On Dec 19, 2023, Co And Impel NeuroPharma Australia Commenced Voluntary Chapter 11 Proceedings
Brief: Impel Pharmaceuticals Says On Dec 1 Michael Kalb Gave Notice Of Resignation From Position As CFO With Last Day To Be December 31
U.S. STOCKS ON THE MOVE-iRobot Corp, Faraday Future, Fisker
U.S. STOCKS ON THE MOVE-iRobot Corp, Fisker Inc, International Seaways Inc
Brief: Impel Pharmaceuticals Receives Delisting Notice From Nasdaq